United Therapeutics Corp. (UTHR) Tops Q1 EPS Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street rises on revived AI momentum as earnings season picks up
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts UTHR Hot Sheet
Price: $589.47 -0.57%
EPS Growth %: -13.3%
Financial Fact:
Total revenues: 408.2M
Today's EPS Names:
OMID, SICP, SCKT, More
EPS Growth %: -13.3%
Financial Fact:
Total revenues: 408.2M
Today's EPS Names:
OMID, SICP, SCKT, More
Join SI Premium – FREE
United Therapeutics Corp. (Nasdaq: UTHR) reported Q1 non-GAAP EPS of $1.29, $0.65 better than the analyst estimate of $0.64. Revenue for the quarter came in at $165.6 million versus the consensus estimate of $178.02 million.
United Therapeutics reported non-GAAP EPS of $1.13 in Q210.
United Therapeutics reported non-GAAP EPS of $1.13 in Q210.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- United Therapeutics Corp. (UTHR) PT Raised to $850 at Cantor Fitzgerald
- Repligen (RGEN) Tops Q3 EPS by 7c ; Offers Guidance
- S&P Global (SPGI) Tops Q3 EPS by 16c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
